Beta Bionics, Inc. is a commercial-stage medical device company engaged in the design, development and commercialization of various solutions to improve the health of insulin-requiring people with diabetes (PWD). The Company's product, the iLet Bionic Pancreas (iLet), is an insulin delivery device cleared by the United States Food and Drug Administration (FDA) to utilize adaptive closed-loop algorithms to autonomously determine every insulin dose without requiring a user to count carbohydrate intake. iLet is used for the treatment of Type 1 diabetes (T1D). The Company's solutions include iLet for Adults, iLet for Children, Bionic Circle App and iLet Simulator. The Company is in the early stages of developing an insulin pump that is designed to adhere directly to the skin and administer insulin without the need for tubing, commonly known in the diabetes industry as a patch pump. It is also in the early stages of developing a bihormonal configuration of the iLet.
종목 코드 BBNX
회사 이름Beta Bionics Inc
상장일Jan 30, 2025
CEOMr. Sean Saint
직원 수291
유형Ordinary Share
회계 연도 종료Jan 30
주소11 Hughes
도시IRVINE
증권 거래소NASDAQ Global Market Consolidated
국가United States of America
우편 번호92618
전화19494277785
웹사이트https://www.betabionics.com
종목 코드 BBNX
상장일Jan 30, 2025
CEOMr. Sean Saint
지난 5년 동안 총
0.00
USD의 배당금이 분배되었습니다.

데이터 없음